Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
52%
Patient
32%
COVID-19
26%
Opportunistic Infection
21%
Retrovirus Infection
21%
Prevalence
18%
Therapeutic Procedure
18%
Infection
18%
Woman
17%
Hepatitis C Virus
15%
Obesity
12%
Hepatitis C
11%
Hispanic
11%
Child
11%
Female
10%
Drug Resistance
9%
Hepatitis B Virus
9%
Hepatitis B
8%
Age
8%
Predictor
8%
Health
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Chemotherapeutic Agent
7%
Drug
7%
Dolutegravir
7%
Hepatitis Virus
7%
Mortality
7%
Combination Therapy
7%
Antiviral Therapy
6%
Follow up
6%
Placebo
6%
Race
6%
Hepatitis B Antigen
6%
Pregnant Adolescent
6%
Screening
5%
Adolescent
5%
Evaluation Study
5%
Hospital
5%
Antiretrovirus Agent
5%
Disparity
5%
Remdesivir
5%
Analysis
5%
Interpersonal Communication
5%
Computed Tomography
5%
Hepatitis B Vaccination
5%
Nursing and Health Professions
Antiretroviral Therapy
52%
Patient
22%
Retrovirus Infection
18%
Opportunistic Infection
18%
Prevalence
18%
Infection
15%
Child
15%
Drug Resistance
11%
Prevention
10%
Hispanic
10%
Primary Medical Care
9%
Adult
9%
Health Care Personnel
9%
Procedures
9%
Time
9%
Human Immunodeficiency Virus Infection
8%
Drug
7%
Evaluation Study
7%
Hepatitis B
6%
Vaccination Policy
6%
Follow up
6%
Diseases
6%
Treatment Outcome
6%
Hospital
6%
Gender
5%
Hepatitis C
5%
Screening
5%
Mortality
5%
Heart Rate Variability
5%
Vaccine Hesitancy
5%
Student
5%
Calculator
5%
Antiviral Therapy
5%
Virus Hepatitis
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
51%
Opportunistic Infection
17%
Retrovirus Infection
17%
Remdesivir
15%
Drug Resistance
14%
Drug
14%
Infection
13%
Antiretrovirus Agent
11%
Prevalence
10%
Clinical Trial
9%
Diseases
8%
Baricitinib
8%
Integrase
7%
Virus
7%
Pharmacokinetics
7%
Placebo
6%
Fusion Inhibitor
5%
Human Immunodeficiency Virus 1
5%
Zidovudine
5%
Hepatitis C Virus
5%
Virus Hepatitis
5%
Hepatitis B
5%
Hepatitis B Surface Antigen
5%
Antiviral Therapy
5%